Finally, recent studies are exploring T cell expressing CD123 chimeric antigen receptor-modified T-cells (CAR T) as a new immunotherapy for the treatment of refractory/relapsing AML and BPDCN. This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.